Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.61 |
| ▸ | RNASEH1 | O60930 | 2/20 | 0.56 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | PDE5A | O76074 | 2/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | DAO | P14920 | 1/20 | 0.46 |
| ▸ | BRD4 | O60885 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL405065 | 0.88 | PDE5A (0.64) | KMT2ARNASEH1ACVR1POLBPDE5A | |
| SCHEMBL405713 | 0.88 | ALDH1A1 (0.48) | KMT2ARNASEH1ACVR1POLBPDE5A | |
| SCHEMBL400190 | 0.85 | KDM4C (0.52) | — | |
| SCHEMBL405399 | 0.84 | RNASEH1 (0.60) | KMT2ARNASEH1ACVR1POLBPDE5A | |
| SCHEMBL401595 | 0.84 | MAPT (0.47) | KMT2ARNASEH1ACVR1POLBKDM4E | |
| SCHEMBL13892327 | 0.83 | TNKS2 (0.57) | KMT2AACVR1GAAPOLBADORA3 | |
| SCHEMBL1553897 | 0.82 | GAA (0.54) | KMT2ARNASEH1GAAPOLBPDE5A | |
| SCHEMBL405407 | 0.81 | POLB (0.57) | RNASEH1POLBPDE5ATSHRKDM4E | |
| SCHEMBL404756 | 0.81 | KDM4E (0.64) | GAAPOLBPKMTSHRKDM4E | |
| SCHEMBL403922 | 0.81 | POLB (0.49) | POLBKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2050739-B1 | QUINAZOLINE DERIVATIVE | ASKA PHARM CO LTD (JP) | 2016-07-06 | — | — | EP | disclosed |
| CN-101501007-B | Quinazoline derivative | ASKA PARMACEUTICAL CO LTD | 2014-01-29 | — | — | CN | disclosed |
| US-8101624-B2 | Quinazoline derivatives | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2012-01-24 | — | — | US | disclosed |
| US-20100113484-A1 | TREATING AGENT OF UROPATHY | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2010-05-06 | — | — | US | disclosed |
| US-20090318478-A1 | QUINAZOLINE DERIVATIVES | ASKA PHARMACEUTICAL CO., LTD. | 2009-12-24 | — | — | US | disclosed |
| EP-2123301-A1 | THERAPEUTIC AGENT FOR URINARY TRACT DISEASE | ASKA Pharmaceutical Co., Ltd. (JP) | 2009-11-25 | — | — | EP | disclosed |
| CN-101557826-A | Therapeutic agent for urinary tract disease | ASKA PHARM CO LTD (JP) | 2009-10-14 | — | — | CN | disclosed |
| CN-101501007-A | Quinazoline derivative | ASKA PARMACEUTICAL CO LTD (JP) | 2009-08-05 | — | — | CN | disclosed |
| EP-2050739-A1 | QUINAZOLINE DERIVATIVE | ASKA Pharmaceutical Co., Ltd. (JP) | 2009-04-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113484-A1 | TREATING AGENT OF UROPATHY | BPHL, PDE12, UROD | KMT2A 2820/4885RNASEH1 974/4885ACVR1 4496/4885 |
| US-20090318478-A1 | QUINAZOLINE DERIVATIVES | PDE9A, PDE3A, PDE5A | KMT2A 3246/4885RNASEH1 254/4885ACVR1 3460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.